• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Prostate cancer screening: French study finds more harm than good from PSA testing

  • in Audio · Oncology
  • — 19 Nov, 2013
Prostate cancer screening: French study finds more harm than good from PSA testing

AMSTERDAM— Organized screening for prostate cancer using the prostate-specific antigen (PSA) test does more harm than good, according to the findings of a French study reported here at the 2013 European Cancer Congress.
With more than half of all French men aged between 50 and 60 having an annual PSA test, Professor Mathieu Boniol PhD, Research Director of the International Prevention Research Institute based in Lyon and his team balanced the side effects and mortality associated with PSA testing against the benefits by using data from the European Randomized Study of Screening for Prostate Cancer (ERSPC) which they compared with published data on the side effects of biopsy and surgery.
The calculation of ‘the number of individuals needed to harm’ associated with PSA was achieved by applying the data to a ‘virtual population’ of 1,000 men aged 55-69 screened using the PSA test and a further 1,000 men not getting the test. The published mortality and side-effect data were then applied to the men being ‘tested’ and a significant down-side of over-diagnosis of prostate cancer — and consequent overtreatment — emerged.
Professor Cora Sternberg, MD, FACP Chief of the Department of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome —who moderated the press conference here on PSA screening — discussed why, she thought PSA testing had not been doing as well as would be hoped in the real world.

You may also like...

  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes 10 Dec, 2007
  • Annual Meeting Daily News Podcasts – June 2nd, 2007 Annual Meeting Daily News Podcasts – June 2nd, 2007 4 Jun, 2007
  • Audio Journal of Oncology in Advance – March 1st, 2007 Audio Journal of Oncology in Advance – March 1st, 2007 2 Mar, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.
  • Next story PDL1 inhibitor brings better responses in smokers with refractory lung cancer
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Childhood Obesity—Whose Business Is It?
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with…
  • Home
  • Audio
  • Prostate cancer screening: French study finds more harm than good from PSA testing

© COPYRIGHT 2020 AUDIOMEDICA.COM.